<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Bispecific-Antibodies on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/bispecific-antibodies/</link><description>Recent content in Bispecific-Antibodies on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Wed, 15 Jul 2026 06:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/bispecific-antibodies/index.xml" rel="self" type="application/rss+xml"/><item><title>T-Cell Engagers in Rheumatology</title><link>https://rheumatologydigest.org/posts/t-cell-engagers-rheumatology/</link><pubDate>Wed, 15 Jul 2026 06:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/t-cell-engagers-rheumatology/</guid><description>A 2026 narrative review of T-cell engagers (TCEs) in autoimmune rheumatic disease — off-the-shelf bispecific antibodies that redirect a patient&amp;rsquo;s own T cells against autoreactive B/plasma cells, pitched as a repeatable, dose-adjustable alternative to CAR-T. Early efficacy across SLE, SSc, RA, myositis and Sjögren&amp;rsquo;s is real but preliminary, and the review&amp;rsquo;s headline problem is under-dosing relative to oncology, which likely drives frequent relapse.</description></item></channel></rss>